Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:50 UTC |
---|
Update Date | 2021-09-14 15:00:47 UTC |
---|
HMDB ID | HMDB0014980 |
---|
Secondary Accession Numbers | - HMDB0060975
- HMDB0061121
- HMDB14980
- HMDB60975
- HMDB61121
|
---|
Metabolite Identification |
---|
Common Name | Oxazepam |
---|
Description | Oxazepam is only found in individuals that have used or taken this drug. It is an intermediate-acting benzodiazepine used to treat alcohol withdrawal and anxiety disorders. It is a metabolite of diazepam, prazepam, temazepam, and clorazepate, and has moderate amnesic, anxiolytic, anticonvulsant, hypnotic, sedative, and skeletal muscle relaxant properties compared to other benzodiazepines (Wikipedia ). Like other benzodiazepines, oxazepam exerts its anxiolytic effects by potentiating the effect of gamma-aminobutyric acid (GABA) on GABA-A receptors through a cooperative mechanism of action. GABA receptors are ionotropic chloride-linked channel receptors that produce inhibitory postsynaptic potentials. When activated by GABA, the GABA receptor/chloride ionophore complex undergoes a conformational change that allows the passage of chloride ions through the channel. Benzodiazepines are believed to exert their effect by increasing the effect of GABA at its receptor. Benzodiazepine binding increases chloride conductance in the presence of GABA by increasing the frequency at which the channel opens. In contrast, barbiturates increase chloride conductance in the presence of GABA by prolonging the time in which the channel remains open. There are 18 subtypes of the GABA receptor subunits. The α2 subunit of the α2β3γ2 receptor complex is thought to mediate anxiolytic effects while the α1 subunit of the α1β2γ2 receptor complex is thought to mediate sedative, anticonvulsant, and anterograde amnesia effects. |
---|
Structure | OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2 InChI=1S/C15H11ClN2O2/c16-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)18-15(20)14(19)17-12/h1-8,15,20H,(H,17,19) |
---|
Synonyms | Value | Source |
---|
(+-)-Oxazepam | ChEBI | (RS)-Oxazepam | ChEBI | Serax | ChEBI | Tazepam | ChEBI | ZAXOPAM | HMDB | WY-3498oxozepam | HMDB | Oxazipam | HMDB | Oxozepam | HMDB | Adumbran | HMDB | Nortemazepam | HMDB | 3-Hydroxynordiazepam | HMDB |
|
---|
Chemical Formula | C15H11ClN2O2 |
---|
Average Molecular Weight | 286.713 |
---|
Monoisotopic Molecular Weight | 286.050905313 |
---|
IUPAC Name | 7-chloro-3-hydroxy-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one |
---|
Traditional Name | oxazepam |
---|
CAS Registry Number | 604-75-1 |
---|
SMILES | OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2 |
---|
InChI Identifier | InChI=1S/C15H11ClN2O2/c16-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)18-15(20)14(19)17-12/h1-8,15,20H,(H,17,19) |
---|
InChI Key | ADIMAYPTOBDMTL-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Benzodiazepines |
---|
Sub Class | 1,4-benzodiazepines |
---|
Direct Parent | 1,4-benzodiazepines |
---|
Alternative Parents | |
---|
Substituents | - 1,4-benzodiazepine
- Aryl chloride
- Aryl halide
- Monocyclic benzene moiety
- Benzenoid
- Cyclic carboximidic acid
- Ketimine
- Alkanolamine
- Azacycle
- Organic 1,3-dipolar compound
- Propargyl-type 1,3-dipolar organic compound
- Organic nitrogen compound
- Organonitrogen compound
- Organochloride
- Organohalogen compound
- Organooxygen compound
- Imine
- Hydrocarbon derivative
- Organopnictogen compound
- Organic oxygen compound
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 205 - 206 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.088 g/L | Not Available | LogP | 2.8 | Not Available |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross SectionsAdduct Type | Data Source | CCS Value (Å2) | Reference |
---|
[M+H]+ | CBM | 162.3 | 30932474 |
|
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Oxazepam,1TMS,isomer #1 | C[Si](C)(C)OC1N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C2NC1=O | 2605.6 | Semi standard non polar | 33892256 | Oxazepam,1TMS,isomer #2 | C[Si](C)(C)N1C(=O)C(O)N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C21 | 2371.2 | Semi standard non polar | 33892256 | Oxazepam,2TMS,isomer #1 | C[Si](C)(C)OC1N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C2N([Si](C)(C)C)C1=O | 2381.5 | Semi standard non polar | 33892256 | Oxazepam,2TMS,isomer #1 | C[Si](C)(C)OC1N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C2N([Si](C)(C)C)C1=O | 2530.5 | Standard non polar | 33892256 | Oxazepam,2TMS,isomer #1 | C[Si](C)(C)OC1N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C2N([Si](C)(C)C)C1=O | 3314.5 | Standard polar | 33892256 | Oxazepam,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C2NC1=O | 2796.5 | Semi standard non polar | 33892256 | Oxazepam,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N1C(=O)C(O)N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C21 | 2660.5 | Semi standard non polar | 33892256 | Oxazepam,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C2N([Si](C)(C)C(C)(C)C)C1=O | 2819.5 | Semi standard non polar | 33892256 | Oxazepam,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C2N([Si](C)(C)C(C)(C)C)C1=O | 2951.7 | Standard non polar | 33892256 | Oxazepam,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C2N([Si](C)(C)C(C)(C)C)C1=O | 3440.5 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental GC-MS | GC-MS Spectrum - Oxazepam EI-B (Non-derivatized) | splash10-0699-7490000000-e90f4b8174c78110a07a | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Oxazepam EI-B (Non-derivatized) | splash10-0pxr-6490000000-98a9035e85eeea7c02e5 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Oxazepam EI-B (Non-derivatized) | splash10-0699-7490000000-e90f4b8174c78110a07a | 2018-05-18 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Oxazepam EI-B (Non-derivatized) | splash10-0pxr-6490000000-98a9035e85eeea7c02e5 | 2018-05-18 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Oxazepam EI-B (Non-derivatized) | splash10-0699-7490000000-e90f4b8174c78110a07a | 2018-05-18 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Oxazepam EI-B (Non-derivatized) | splash10-0pxr-6490000000-98a9035e85eeea7c02e5 | 2018-05-18 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Oxazepam EI-B (Non-derivatized) | splash10-0699-7490000000-e90f4b8174c78110a07a | 2018-05-18 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Oxazepam EI-B (Non-derivatized) | splash10-0pxr-6490000000-98a9035e85eeea7c02e5 | 2018-05-18 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Oxazepam EI-B (Non-derivatized) | splash10-0699-7490000000-e90f4b8174c78110a07a | 2018-05-18 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Oxazepam EI-B (Non-derivatized) | splash10-0pxr-6490000000-98a9035e85eeea7c02e5 | 2018-05-18 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Oxazepam EI-B (Non-derivatized) | splash10-0699-7490000000-e90f4b8174c78110a07a | 2018-05-18 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Oxazepam EI-B (Non-derivatized) | splash10-0pxr-6490000000-98a9035e85eeea7c02e5 | 2018-05-18 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Oxazepam EI-B (Non-derivatized) | splash10-0699-7490000000-e90f4b8174c78110a07a | 2018-05-18 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Oxazepam EI-B (Non-derivatized) | splash10-0pxr-6490000000-98a9035e85eeea7c02e5 | 2018-05-18 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Oxazepam EI-B (Non-derivatized) | splash10-0699-7490000000-e90f4b8174c78110a07a | 2018-05-18 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Oxazepam EI-B (Non-derivatized) | splash10-0pxr-6490000000-98a9035e85eeea7c02e5 | 2018-05-18 | HMDB team, MONA, MassBank | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Oxazepam GC-MS (Non-derivatized) - 70eV, Positive | splash10-052f-0290000000-addf4d0fa6f665ee3caf | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Oxazepam GC-MS (1 TMS) - 70eV, Positive | splash10-0ul3-3769000000-05c35aec34504fd564f2 | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Oxazepam GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | MS | Mass Spectrum (Electron Ionization) | splash10-05r0-5590000000-87245820addec0215473 | 2014-09-20 | Not Available | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Oxazepam LC-ESI-ITFT , negative-QTOF | splash10-0a4i-0090000000-dc62fcc1bbffbe41a418 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oxazepam LC-ESI-ITFT , negative-QTOF | splash10-000i-0090000000-0babffe4ebd04774afee | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oxazepam LC-ESI-ITFT , negative-QTOF | splash10-000i-0090000000-93028caba51f80d16e67 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oxazepam LC-ESI-ITFT , negative-QTOF | splash10-0006-0490000000-e36258d846328fd12f7d | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oxazepam LC-ESI-ITFT , negative-QTOF | splash10-0udi-0900000000-d4bd0b0355dc42f3606f | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oxazepam LC-ESI-ITFT , negative-QTOF | splash10-000i-0090000000-cb90c6162b5e9a189120 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oxazepam LC-ESI-ITFT , negative-QTOF | splash10-000i-0090000000-cfdd9662d1f355ecf572 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oxazepam LC-ESI-ITFT , negative-QTOF | splash10-052f-0090000000-1c26508a42811abbe1cb | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oxazepam LC-ESI-ITFT , negative-QTOF | splash10-0udl-0980000000-870c5260836b760916d2 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oxazepam LC-ESI-ITFT , negative-QTOF | splash10-0006-0090000000-f0561f08464034626ee2 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oxazepam LC-ESI-ITFT , negative-QTOF | splash10-0a4i-0090000000-d55c5dfc5658fa7a4e05 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oxazepam LC-ESI-QFT , negative-QTOF | splash10-000i-0090000000-7682f5c8dc13b49aa59e | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oxazepam LC-ESI-ITFT , positive-QTOF | splash10-014i-0090000000-526eef46646595e92a99 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oxazepam LC-ESI-ITFT , positive-QTOF | splash10-000i-0090000000-21ba02c0de7b6e8c51ff | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oxazepam LC-ESI-ITFT , positive-QTOF | splash10-014r-0090000000-61c68689382573975141 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oxazepam LC-ESI-ITFT , positive-QTOF | splash10-0006-0090000000-74e04f10a2b801bba9ba | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oxazepam LC-ESI-ITFT , positive-QTOF | splash10-0006-0490000000-31f82dff12f0e9088719 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oxazepam LC-ESI-ITFT , positive-QTOF | splash10-0f6x-0960000000-90758cc09aa77510b07c | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Oxazepam LC-ESI-ITFT , positive-QTOF | splash10-0w2c-1920000000-c885875f53b407082d2c | 2017-09-14 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oxazepam 10V, Positive-QTOF | splash10-000i-0090000000-0c78f95c205c4133ad3f | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oxazepam 20V, Positive-QTOF | splash10-000i-0190000000-a47bbd218c1fcbdd15d7 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oxazepam 40V, Positive-QTOF | splash10-0w29-3940000000-50031d5defc4cf611b69 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oxazepam 10V, Negative-QTOF | splash10-000i-0090000000-9a2555f0640b1be17184 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oxazepam 20V, Negative-QTOF | splash10-000i-0290000000-3ba9539523b06dcf9f55 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Oxazepam 40V, Negative-QTOF | splash10-002f-9240000000-ef1fda9d63afce90fe36 | 2016-08-03 | Wishart Lab | View Spectrum |
|
---|